Breast Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017


#41882

58pages

GlobalData

$ 2000

In Stock


GlobalData, the industry analysis specialist, has released its new report, “Breast Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global breast cancer market. The report identifies the key trends shaping and driving the global breast cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global breast cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

 

GlobalData’s analysis suggests that the global breast cancer market was worth $8.7 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 6% for the next eight years, to reach $13.86 billion by 2017. The high projected growth rate is primarily attributable to a strong pipeline. Increases in the treatment seeking population, the diagnosis population, and the availability of new first-in-class therapies with better safety and efficacy are expected to drive the growth of the breast cancer market. 

 

Scope

 

The report provides information on the key drivers and challenges of the breast cancer market. Its scope includes:

 

  • Annualized global breast cancer market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as GnRH antagonists, GnRH synergists, aromatase inhibitors, antiprogestins and steroid sulfatase inhibitors.
  • Analysis of the current and future competition in the global breast cancer market. Key market players covered are Bayer Healtcare Pharmaceuticals, Pfizer Inc, Neurocrine Biosciences Inc., Æterna Zentaris Inc. and Repros Therapeutics Inc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the breast cancer therapeutics market.

Reasons to buy

 

The report will enhance your decision making capability. It will allow you to:

 

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global breast cancer market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global breast cancer market landscape? - Identify, understand and capitalize.

Table of Content

1 Table of contents 2

1.1 List of Tables 4
1.2 List of Figures 4

2 Breast Cancer Introduction 5
2.1 Overview 5
2.2 TNM Classification 5
2.3 Risk Factors 7
2.4 Signs and Symptoms 7
2.5 Diagnosis 7
2.6 GlobalData Pipeline Report Guidance 8

3 Breast Cancer Market: Market Characterization 9
3.1 Overview 9
3.2 Breast Cancer Market Size 9
3.3 Breast Cancer Market Forecast and CAGR 10
3.4 Drivers and Barriers for the Breast Cancer Market 12
3.4.1 Drivers for the Breast Cancer Market 12
3.4.2 Barriers for the Breast Cancer Market 12
3.5 Opportunity and Unmet Need 13
3.6 Key Takeaway 14

4 Breast Cancer Therapeutics: Competitive Assessment 15
4.1 Overview 15
4.2 Strategic Competitor Assessment 15
4.3 Product Profiles of the Major Marketed Products in the Breast Cancer Market 16
4.3.1 Abraxane (albumin bound paclitaxel) 16
4.3.2 Arimidex (anastrozole) 17
4.3.3 Femara (letrozole) 18
4.3.4 Herceptin (trastuzumab) 19
4.3.5 Taxotere (docetaxel) 22
4.3.6 Xeloda (capecitabine) 23
4.3.7 Tykerb (Lapatinib) 24
4.3.8 Avastin (bevacizumab) + Paclitaxel 25
4.4 Key Takeaway 26

5 Breast Cancer Therapeutics: Pipeline Assessment 27
5.1 Overview 27
5.2 Strategic Pipeline Assessment 27
5.2.1 Technology Trends Analytic Framework 27
5.3 Molecule Profile for Promising Drugs under Clinical Development 28
5.3.1 Halaven (Eribulin) 28
5.3.2 Afinitor 29
5.3.3 NeuVax 30
5.4 Breast Cancer Therapeutics Market Clinical Pipeline by Mechanism of Action 31
5.5 Breast Cancer Pipeline Pipeline by Clinical Phases of Development 33
5.5.1 Breast Cancer Therapeutics Phase III Clinical Pipeline 33
5.5.2 Breast Cancer Therapeutics Phase II Clinical Pipeline 34
5.5.3 Breast Cancer Therapeutics Phase I Clinical Pipeline 36
5.5.4 Breast Cancer Therapeutics Preclinical and Discovery Pipeline 37
5.6 Key Takeaway 38

6 Breast Cancer Therapeutics: Implications for Future Market Competition 39

7 Breast Cancer Therapeutics: Future Players in the Breast Cancer Market 40

7.1 Introduction 40
7.2 Novartis AG 40
7.2.1 Company Overview 40
7.2.2 Oncology Portfolio 41
7.3 GlaxoSmithKline plc (GSK) 42
7.3.1 Overview 42
7.4 F. Hoffmann-La Roche Ltd. 43
7.4.1 Overview 43
7.4.2 Business Description 43
7.5 Pfizer Inc. 45
7.5.1 Overview 45
7.5.2 Business Description 45
7.6 Eli Lilly and Company 48
7.6.1 Overview 48
7.6.2 Business Description 48
7.7 Eisai Co., Ltd. 49
7.7.1 Company Overview 49
7.7.2 Business Description 49

8 Breast Cancer Market: Appendix 52
8.1 Market Definition 52
8.2 Abbreviations 52
8.3 Research Methodology 53
8.3.1 Coverage 53
8.3.2 Secondary Research 53
8.3.3 Forecasting 54
8.3.4 Primary Research 57
8.3.5 Expert Panel Validation 57
8.4 Contact Us 57
8.5 Disclaimer 57
8.6 Sources 58


Table 1: Breast Cancer Stage Classification 5
Table 2: Breast Cancer Therapeutics, Global, Revenue ($bn), 20012009 10
Table 3: Breast Cancer Therapeutics, Global, Revenue Forecast ($bn), 20092017 11
Table 4: Other 32% Consists of the Following Mechanisms of Action, 2010 32
Table 5: Breast Cancer Pipeline, Phase III, 2010 33
Table 6: Breast Cancer Pipeline, Phase II, 2010 34
Table 7 Breast Cancer Pipeline, Phase I, 2010 36
Table 8 Breast Cancer Pipeline, Pre-clinical and Discovery Phase, 2010 37
Table 9: Novartis Oncology Pipeline, 2010 41
Table 10: GlaxoSmithKline Oncology Pipeline, 2010 43
Table 11: F. Hoffmann-La Roche Ltd Oncology Pipeline, 2010 44
Table 12: Pfizer Oncology Pipeline, 2010 47
Table 13: Eli Lilly and Company Oncology Pipeline, 2010 49
Table 14: Eisai Oncology Pipeline, 2010 51


Figure 1: Breast Cancer Therapeutics, Global, Revenue Forecast ($bn), 20092017 10
Figure 2: Breast Cancer Therapeutics, Global, Revenue Forecast ($bn), 20092017 11
Figure 3: Opportunity and Unmet Need in the Breast Cancer Market, 2010 13
Figure 4: Strategic Competitor Assessment of the Marketed Products for Breast Cancer, 2010 15
Figure 5: Technology Trends Analytic Framework of the Breast Cancer Pipeline, 2010 27
Figure 6: Technology Trends Analytic Framework of the Breast Cancer Pipeline Description, 2010 28
Figure 7: Breast Cancer Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 31
Figure 8: Breast Cancer Pipeline by Phase of Clinical Development, 2010 33
Figure 9: Implications for Future Market Competition in Breast Cancer Therapeutics, 2010 39
Figure 10: Breast Cancer Therapeutics Market Clinical Pipeline by Company, 2010 40
Figure 11: GlobalData Market Forecasting Model 56